DaVita: More Volatile But Better Upside Than Fresenius
DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare reimbursement and lack of dividend heighten risk. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it reverts to historical valuation multiples.
DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
DaVita Inc. ( DVA ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe Research, LLC Presentation Justin Lake Wolfe Research, LLC All right. Good morning.
3 Warren Buffett Stocks to Buy Hand Over Fist in November
DaVita is cheap considering its long-term growth potential. Buy Kraft Heinz for its high yield, stay for the restructuring that could unlock the food company's underlying value.
DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y
DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.
DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript
DaVita Inc. ( DVA ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Nic Eliason - Group Vice President of Investor Relations Javier Rodriguez - CEO & Executive Director Joel Ackerman - CFO & Treasurer Conference Call Participants Kevin Fischbeck - BofA Securities, Research Division Andrew Mok - Barclays Bank PLC, Research Division Albert Rice - UBS Investment Bank, Research Division Pito Chickering - Deutsche Bank AG, Research Division Justin Lake - Wolfe Research, LLC Ryan Langston - TD Cowen, Research Division Presentation Operator Good evening. My name is Michelle, and I will be your conference facilitator today.
DaVita HealthCare (DVA) Q3 Earnings Lag Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $2.59 per share a year ago.
DaVita misses quarterly profit estimates on rising costs, lower volumes
DaVita missed Wall Street estimates for third-quarter profit on Wednesday, as the kidney dialysis provider grappled with rising patient care costs and declining treatment volumes.
Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?
DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $127.89, denoting a -2.4% move from the preceding trading day.
DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare (DVA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, DaVita HealthCare (DVA) closed at $128, marking a -1.62% move from the previous day.
